Form 4: Oragenics CFO Janet Huffman Acquires 80,000 Stock Options
SEC Form 4 Filing
Janet Huffman, CFO of Oragenics Inc., reports the acquisition of 80,000 stock options that vest immediately.
Summary
- Janet Huffman, the Chief Financial Officer of Oragenics Inc. (OGEN), filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on September 19, 2024.
- Huffman acquired 80,000 employee stock options with an exercise price of $0.48.
- These options vest immediately and expire on September 19, 2034.
- The options are related to Oragenics' 2021 Equity Incentive Plan, as amended.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard executive compensation practice.
Positives
- The immediate vesting of the options could incentivize the CFO to perform well.
Industry Context
This type of stock option grant is a common practice for incentivizing executives in publicly traded companies, aligning their interests with those of the shareholders.
Stakeholder Impact
- The stock option grant could potentially align the CFO's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/19/2024 | Date of the transaction: Janet Huffman acquired 80,000 stock options. |
| 09/19/2024 | Options become exercisable. |
| 09/19/2034 | Expiration date of the stock options. |
| 09/20/2024 | Date of the Form 4 filing. |
Keywords
Oragenics, OGEN, Janet Huffman, CFO, stock options, Form 4, SEC filing, equity incentive plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.